Proteon Therapeutics Investor Seeks To Halt $42M Merger
A Proteon Therapeutics Inc. investor has asked a New York federal judge to halt the biopharmaceutical company's planned $42.5 million merger with ArTara Therapeutics, alleging Proteon made misleading financial statements to...To view the full article, register now.
Already a subscriber? Click here to view full article